3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)prop-2-enenitrile | 339555-31-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)prop-2-enenitrile
• 英文别名: (E)-3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)prop-2-enenitrile
• CAS: 339555-31-6
• 化学式: C₁₁H₁₁N₃
• 分子量: 185.228
• InChiKey: IOTXRGQFQUKWMH-DAFODLJHSA-N

物化性质

• 沸点：
  437.8±37.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  48.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)prop-2-enenitrile 在 镍 ammonium hydroxide 、 硫酸 、 水 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 仲丁醇 为溶剂， 20.0~50.0 ℃ 、275.79 kPa 条件下， 反应 37.0h， 生成 (3S)-3-(6-methoxypyridin-3-yl)-3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl}propionic acid
  参考文献：
  名称：

  An Efficient Synthesis of an α_vβ₃ Antagonist

  摘要：

  A practical preparation of an alpha(v)beta(3) antagonist is reported. The antagonist consists of three key components, a tetrahydronaphthyridine moiety, a beta-alanine moiety, and a central imidazolidone moiety. The tetrahydronaphthyridine component was prepared using two different methods, both of which relied on variations of the Friedlander reaction to establish the desired regiochemistry. The beta-alanine component was prepared using Davies' asymmetric 1,4-addition methodology as the key stereo-defining step. The central imidazolidone portion was created from these two components using an effective three-step cyclization protocol. Thus, a highly convergent process for the drug candidate was defined.

  DOI：

  10.1021/jo030297u
• 作为产物：
  描述：

  2-氨基-3-吡啶甲醛 在 platinum(IV) oxide 盐酸 、 sodium hydroxide 、 氢气 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 20.0~85.0 ℃ 、101.33 kPa 条件下， 反应 21.5h， 生成 3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)prop-2-enenitrile
  参考文献：
  名称：

  An Efficient Synthesis of an α_vβ₃ Antagonist

  摘要：

  A practical preparation of an alpha(v)beta(3) antagonist is reported. The antagonist consists of three key components, a tetrahydronaphthyridine moiety, a beta-alanine moiety, and a central imidazolidone moiety. The tetrahydronaphthyridine component was prepared using two different methods, both of which relied on variations of the Friedlander reaction to establish the desired regiochemistry. The beta-alanine component was prepared using Davies' asymmetric 1,4-addition methodology as the key stereo-defining step. The central imidazolidone portion was created from these two components using an effective three-step cyclization protocol. Thus, a highly convergent process for the drug candidate was defined.

  DOI：

  10.1021/jo030297u

文献信息

• [EN] COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE<br/>[FR] COMPOSITION ET PROCÉDÉS DE TRAITEMENT DE MALADIE RÉNALE CHRONIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016154369A1

  公开（公告）日：2016-09-29

  This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.

  这项发明涉及利用RGD拟态整合素受体拮抗剂治疗慢性肾病，包括糖尿病肾病、局灶节段性肾小球硬化（FSGS）、肾病综合征、非糖尿病性慢性肾病、肾脏纤维化或急性肾损伤，可以作为单一药剂或与其他药剂联合使用。
• Compositions Methods for Treating Chronic Kidney Disease
  申请人：COX Jason M.

  公开号：US20180110762A1

  公开（公告）日：2018-04-26

  This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.
• An Efficient Synthesis of an α_vβ₃ Antagonist
  作者：Nobuyoshi Yasuda、Yi Hsiao、Mark S. Jensen、Nelo R. Rivera、Chunhua Yang、Kenneth M. Wells、James Yau、Michael Palucki、Lushi Tan、Peter G. Dormer、Ralph P. Volante、David L. Hughes、Paul J. Reider

  DOI：10.1021/jo030297u

  日期：2004.3.1

  A practical preparation of an alpha(v)beta(3) antagonist is reported. The antagonist consists of three key components, a tetrahydronaphthyridine moiety, a beta-alanine moiety, and a central imidazolidone moiety. The tetrahydronaphthyridine component was prepared using two different methods, both of which relied on variations of the Friedlander reaction to establish the desired regiochemistry. The beta-alanine component was prepared using Davies' asymmetric 1,4-addition methodology as the key stereo-defining step. The central imidazolidone portion was created from these two components using an effective three-step cyclization protocol. Thus, a highly convergent process for the drug candidate was defined.